Folgen
Haralabos Kalofonos
Haralabos Kalofonos
Professor of Medical Oncology, Division of Oncology, Department of Medicine University of Patras
Bestätigte E-Mail-Adresse bei upatras.gr
Titel
Zitiert von
Zitiert von
Jahr
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
39532017
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ...
New England Journal of Medicine 379 (23), 2220-2229, 2018
26662018
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
25712018
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
9742020
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6352017
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE …
N Thatcher, FR Hirsch, AV Luft, A Szczesna, TE Ciuleanu, M Dediu, ...
The lancet oncology 16 (7), 763-774, 2015
5382015
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
AA Argyriou, G Iconomou, HP Kalofonos
Blood, The Journal of the American Society of Hematology 112 (5), 1593-1599, 2008
5192008
A review on oxaliplatin-induced peripheral nerve damage
AA Argyriou, P Polychronopoulos, G Iconomou, E Chroni, HP Kalofonos
Cancer treatment reviews 34 (4), 368-377, 2008
3942008
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
3772020
Adjuvant MAGE-A3 immunotherapy in resected non–small-cell lung cancer: phase II randomized study results
J Vansteenkiste, M Zielinski, A Linder, J Dahabreh, EE Gonzalez, ...
Journal of Clinical Oncology 31 (19), 2396-2403, 2013
3642013
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, B Frigeni, ...
Annals of Oncology 24 (2), 454-462, 2013
3422013
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non–small-cell lung cancer: a phase III randomized trial
P Kosmidis, N Mylonakis, C Nicolaides, C Kalophonos, E Samantas, ...
Journal of clinical oncology 20 (17), 3578-3585, 2002
3352002
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
AA Argyriou, AP Kyritsis, T Makatsoris, HP Kalofonos
Cancer management and research, 135-147, 2014
3172014
Peripheral nerve damage associated with administration of taxanes in patients with cancer
AA Argyriou, M Koltzenburg, P Polychronopoulos, S Papapetropoulos, ...
Critical reviews in oncology/hematology 66 (3), 218-228, 2008
3162008
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial
AA Argyriou, E Chroni, A Koutras, J Ellul, S Papapetropoulos, G Katsoulas, ...
Neurology 64 (1), 26-31, 2005
3012005
Financial crisis and austerity measures in Greece: their impact on health promotion policies and public health care
AA Ifanti, AA Argyriou, FH Kalofonou, HP Kalofonos
Health policy 113 (1-2), 8-12, 2013
2992013
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer
AA Argyriou, G Cavaletti, C Briani, R Velasco, J Bruna, M Campagnolo, ...
Cancer 119 (2), 438-444, 2013
2582013
Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real
AA Argyriou, K Assimakopoulos, G Iconomou, F Giannakopoulou, ...
Journal of pain and symptom management 41 (1), 126-139, 2011
2552011
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study
E Briasoulis, H Kalofonos, D Bafaloukos, E Samantas, G Fountzilas, ...
2532000
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised …
DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ...
The Lancet 390 (10109), 2266-2277, 2017
2382017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20